| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chronic Kidney Disease |

,
,
,
Departments of * Medicine and
Community Health Sciences, University of Calgary, Calgary, and
Institute of Health Economics and
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Address correspondence to: Dr. Brenda Hemmelgarn, Division of Nephrology, Foothills Hospital, 1403 29th St. NW, Calgary, Alberta, Canada, T2N 2T9. Phone: 403-944-2745; Fax: 403-944-2876; E-mail: brenda.hemmelgarn{at}calgaryhealthregion.ca
Received for publication August 15, 2006. Accepted for publication December 11, 2006.
The effectiveness of multidisciplinary care (MDC) in improving health outcomes for patients with chronic kidney disease (CKD) is uncertain. This study sought to determine the association among MDC, survival, and risk for hospitalization among elderly outpatients with CKD. A total of 6978 patients who were 66 yr and older and had CKD were identified between July 1 and December 31, 2001, and followed to December 31, 2004; 187 (2.7%) were followed in an MDC clinic. Logistic regression was used to determine the propensity score (probability of MDC) for each patient, and MDC and non-MDC patients then were matched 1:1 on the basis of their score. A Cox model was used to determine the association between MDC and risk for death and hospitalization. After adjustment for age, gender, baseline GFR, diabetes, and comorbidity score, there was a 50% reduction in the risk for death for the MDC compared with the non-MDC group (hazard ratio [HR] 0.50; 95% confidence interval [CI] 0.35 to 0.71). There was no difference in the risk for all-cause (HR 0.83; 95% CI 0.64 to 1.06) or cardiovascular-specific hospitalization (HR 0.76; 95% CI 0.54 to 1.06) for the MDC compared with the non-MDC group. In conclusion, it was found that MDC was associated with a significant reduction in the risk for all-cause mortality and, although not statistically significant, a trend toward a reduction in risk for all-cause and cardiovascular-specific hospitalizations. The benefits of MDC and an assessment of their economic impact should be tested in a randomized, controlled trial.
Related Article
Clin. J. Am. Soc. Nephrol. 2007 2: 277-283.
This article has been cited by other articles:
![]() |
M. T. James, K. B. Laupland, M. Tonelli, B. J. Manns, B. F. Culleton, B. R. Hemmelgarn, and for the Alberta Kidney Disease Network Risk of Bloodstream Infection in Patients With Chronic Kidney Disease Not Treated With Dialysis Arch Intern Med, November 24, 2008; 168(21): 2333 - 2339. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Z. Shariff, M. S. Cuerden, A. K. Jain, and A. X. Garg The Secret of Immortal Time Bias in Epidemiologic Studies J. Am. Soc. Nephrol., May 1, 2008; 19(5): 841 - 843. [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673